Cannabinoid Derivative Compositions With Reduced Adverse Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for cannabinoid compounds with therapeutic benefits for treating conditions like inflammatory bowel disease and estrogen receptor-related diseases while minimizing adverse effects.
Innovation Solution
Development of novel cannabinoid derivatives represented by the structure of formula I, including various alkyl, alkenyl, and alkynyl substitutions, which can be used in pharmaceutical compositions for treating these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (corticosteroids and immunosuppressives) are used to treat inflammatory bowel disease, then therapeutic efficacy is achieved, but significant side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of cannabinoid compounds through various substitutions (R1-R8 groups, X being C, CH, or CD, optional second carbon-carbon bond) to create novel derivatives with improved therapeutic profiles. These structural parameter changes aim to enhance efficacy while reducing adverse effects compared to conventional therapies.
Solution Approach 2:
The patent creates composite pharmaceutical compositions that combine novel cannabinoid derivatives with other therapeutic agents or formulations. This composite approach allows for synergistic effects that can improve therapeutic outcomes while minimizing the harmful side effects associated with single-agent conventional therapies.
2Reliability
If existing cannabinoid compounds are used to treat inflammatory bowel disease, then some therapeutic benefit is achieved, but adverse effects remain significant
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substitutions at particular positions on the cannabinoid molecular structure (R1-R8 substituents, heterocyclic formations). These localized structural modifications are designed to enhance therapeutic activity at the target site while reducing off-target adverse effects.
Solution Approach 2:
The patent systematically varies chemical parameters including the presence of deuterium (X = C, CH, or CD), the nature of alkyl/alkenyl/alkynyl groups (R1-R8), and the optional second carbon-carbon bond to optimize the balance between therapeutic benefit and adverse effects for cannabinoid compounds.
3Reliability
If novel cannabinoid derivatives with multiple structural variations are developed, then therapeutic efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the cannabinoid molecular structure into distinct functional regions with specific substituents (R1-R8 groups, X position, heterocyclic formations). This segmented approach allows for systematic optimization of each region's contribution to therapeutic efficacy while managing overall molecular complexity.
Solution Approach 2:
The patent creates a universal platform of cannabinoid derivatives where a core structure can accommodate multiple substitution patterns (R1-R8, X variations, optional bonds). This multi-functional framework allows a single parent compound to generate multiple therapeutic agents with different efficacy and safety profiles, reducing the need to develop entirely separate molecular scaffolds.
Data Source
AI summary
The present invention provides cannabinoid derivatives, pharmaceutical compositions comprising same, and methods of use thereof as medicaments.